[go: up one dir, main page]

CY1119912T1 - Αντιγονα και συνδυασμοι αντιγονων pseudomonas - Google Patents

Αντιγονα και συνδυασμοι αντιγονων pseudomonas

Info

Publication number
CY1119912T1
CY1119912T1 CY20181100174T CY181100174T CY1119912T1 CY 1119912 T1 CY1119912 T1 CY 1119912T1 CY 20181100174 T CY20181100174 T CY 20181100174T CY 181100174 T CY181100174 T CY 181100174T CY 1119912 T1 CY1119912 T1 CY 1119912T1
Authority
CY
Cyprus
Prior art keywords
antigon
combinations
antigens
pseudomonas antigens
pseudomonas aeruginosa
Prior art date
Application number
CY20181100174T
Other languages
English (en)
Inventor
Vega Masignani
Maria Scarselli
Roberto Petracca
Irene BIANCONI
Alessandra BRAGONZI
Beatriz ALCALA' FRANCO
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1119912T1 publication Critical patent/CY1119912T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ένα αποτελεσματικό εμβόλιο Pseudomonas aeruginosa μπορεί να απαιτεί ένα ή περισσότερα αντιγονικά συστατικά, και έτσι ταυτοποιούνται ποικίλα αντιγόνα Pseudomonas aeruginosa για χρήση σε ανοσοποίηση. Τα εν λόγω πολυπεπτίδια μπορεί προαιρετικώς να χρησιμοποιηθούν σε συνδυασμό με άλλα νοσοκομειακά αντιγόνα.
CY20181100174T 2012-11-30 2018-02-13 Αντιγονα και συνδυασμοι αντιγονων pseudomonas CY1119912T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201221638 2012-11-30
PCT/EP2013/074864 WO2014083060A2 (en) 2012-11-30 2013-11-27 Pseudomonas antigens and antigen combinations

Publications (1)

Publication Number Publication Date
CY1119912T1 true CY1119912T1 (el) 2018-06-27

Family

ID=49681020

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100174T CY1119912T1 (el) 2012-11-30 2018-02-13 Αντιγονα και συνδυασμοι αντιγονων pseudomonas

Country Status (25)

Country Link
US (3) US9987344B2 (el)
EP (2) EP2925355B1 (el)
JP (2) JP6340011B2 (el)
KR (1) KR20150100665A (el)
CN (2) CN105142666A (el)
AU (2) AU2013351182C1 (el)
BR (1) BR112015012762A2 (el)
CA (1) CA2892688A1 (el)
CY (1) CY1119912T1 (el)
DK (1) DK2925355T3 (el)
ES (2) ES2656510T3 (el)
HR (1) HRP20180039T1 (el)
HU (1) HUE036158T2 (el)
IL (2) IL238987B (el)
LT (1) LT2925355T (el)
MX (2) MX366876B (el)
NO (1) NO2925355T3 (el)
PL (1) PL2925355T3 (el)
PT (1) PT2925355T (el)
RS (1) RS56886B1 (el)
RU (2) RU2018137673A (el)
SG (2) SG10201706671WA (el)
SI (1) SI2925355T1 (el)
SM (1) SMT201800011T1 (el)
WO (1) WO2014083060A2 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011348396A1 (en) * 2010-12-23 2013-07-04 Valneva Austria Gmbh OprF/I agents and their use in hospitalized and other patients
US20180201656A1 (en) 2015-07-04 2018-07-19 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting Pseudomonas Aeruginosa
CN105732778A (zh) * 2016-03-02 2016-07-06 中国人民解放军第三军医大学 铜绿假单胞菌重组蛋白OprL及制备方法和应用
CN110922455B (zh) * 2019-12-28 2023-01-13 重庆艾力彼生物科技有限公司 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE3718591A1 (de) 1987-06-03 1988-12-15 Behringwerke Ag Aeusseres membranprotein f von pseudomonas aeruginosa
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
DK0582581T3 (da) 1991-03-01 1999-11-08 Minnesota Mining & Mfg 1,2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
EP0648271B1 (en) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0911413A3 (en) 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE69425901T2 (de) 1993-11-16 2001-04-26 Skyepharma Inc., San Diego Vesikel mit gesteuerter wirkstofffreisetzung
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0717106B1 (en) 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
BR9907884A (pt) 1998-02-12 2000-10-24 American Cyanamid Co Composição de vacina, processos para gerar uma resposta imune em um antìgeno pneumocócico, para aumentar resposta de ifn-gama em uma vacina pneumocócica, e para gerar anticorpos de fixação complementar para uma resposta protetora a um patógeno, composição imunogênica, e, processo para gerar uma resposta imune em um antìgeno meningocócico
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
KR100704826B1 (ko) 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
AP2006003503A0 (en) 1999-09-25 2006-02-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US6551759B2 (en) 2000-06-13 2003-04-22 Agfa-Gevaert Direct-to-plate flexographic printing plate precursor
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
CA2468552C (en) 2001-11-27 2011-09-20 Anadys Pharmaceuticals, Inc. 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
HUE056842T2 (hu) 2005-06-27 2022-03-28 Pfizer Ireland Pharmaceuticals Immunogén készítmény
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
HRP20130023T1 (hr) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
WO2009005040A1 (ja) 2007-06-29 2009-01-08 Meiji Seika Kaisha Ltd. 緑膿菌の外膜タンパク質pa4710
ES2668909T3 (es) * 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
GB2480773B (en) * 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
WO2010107778A1 (en) 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
AU2011348396A1 (en) 2010-12-23 2013-07-04 Valneva Austria Gmbh OprF/I agents and their use in hospitalized and other patients

Also Published As

Publication number Publication date
BR112015012762A2 (pt) 2017-09-12
ES2826555T3 (es) 2021-05-18
RU2015125699A (ru) 2017-01-11
SG10201706671WA (en) 2017-09-28
MX2019008779A (es) 2019-09-10
MX2015006791A (es) 2016-01-14
KR20150100665A (ko) 2015-09-02
AU2013351182C1 (en) 2018-11-08
US20150322116A1 (en) 2015-11-12
SG11201504258RA (en) 2015-07-30
LT2925355T (lt) 2018-03-26
WO2014083060A2 (en) 2014-06-05
IL238987B (en) 2019-08-29
IL238987A0 (en) 2015-07-30
JP6340011B2 (ja) 2018-06-06
SI2925355T1 (en) 2018-04-30
JP2018135388A (ja) 2018-08-30
WO2014083060A3 (en) 2014-08-28
US9987344B2 (en) 2018-06-05
CN111249455A (zh) 2020-06-09
NO2925355T3 (el) 2018-04-14
AU2013351182A1 (en) 2015-06-18
MX366876B (es) 2019-07-29
US20200360504A1 (en) 2020-11-19
IL267657A (en) 2019-08-29
RU2018137673A (ru) 2019-03-22
CA2892688A1 (en) 2014-06-05
JP2016502533A (ja) 2016-01-28
HRP20180039T1 (hr) 2018-04-06
EP3345617A1 (en) 2018-07-11
AU2018203852B2 (en) 2020-02-27
EP3345617B1 (en) 2020-08-26
ES2656510T3 (es) 2018-02-27
US20180256701A1 (en) 2018-09-13
AU2018203852A1 (en) 2018-06-21
SMT201800011T1 (it) 2018-05-02
AU2013351182B2 (en) 2018-03-08
CN105142666A (zh) 2015-12-09
EP2925355A2 (en) 2015-10-07
RS56886B1 (sr) 2018-04-30
PL2925355T3 (pl) 2018-06-29
HUE036158T2 (hu) 2018-06-28
EP2925355B1 (en) 2017-11-15
DK2925355T3 (en) 2018-01-15
PT2925355T (pt) 2018-02-05

Similar Documents

Publication Publication Date Title
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
EP3668539A4 (en) ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
EP3550336A4 (en) OPTICAL BODY, BROADCAST PLATE, DISPLAY DEVICE, PROJECTION DEVICE AND LIGHTING DEVICE
CY1123672T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
BR112015032224A2 (pt) anticorpos anti-fcrh5
MX2015016627A (es) Vacuna para la malaria.
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
MX2016003744A (es) Anticuerpos tem8 y su uso.
CY1119912T1 (el) Αντιγονα και συνδυασμοι αντιγονων pseudomonas
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX377714B (es) Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
EP3550338A4 (en) REFLECTANCE TYPE BROADCAST PLATE, DISPLAY DEVICE, PROJECTION DEVICE AND LIGHTING DEVICE